Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEDAR: Cryoablation in Metastatic Cancer
NCT04150939Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2019
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial in malignant neoplasm, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Best objective response at 12 months. Started Dec 2019; status: active, not recruiting.
02
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT04150939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150939.